Dr. AG has advanced cell therapy technology and mature experience: he started cell therapy in China from 1993, and is the initiator and main promoter of tumor cell therapy in China. The tumor targeted cell therapy promoted by him has made important progress, demonstrated the tumor cell therapy in China and established a standardized treatment system, forming a new model of individualized treatment of tumors. In 1990s, based on the systematic introduction of international advanced cell therapy technologies (CIK, DC, HSP, SP, immune reconstruction, tumor bank, TAA, etc.), the research on tumor cell technology and clinical treatment was carried out. In 2000, the company took the lead in setting up a specialized cell technology company with tumor cell therapy as the core, promoting the utilization of tumor cell resources and tumor cell and molecular therapy, and exploring possible norms and standards of tumor cell therapy technology in China. He has a high level of theoretical and practical experience in promoting the industrialization of modern science and technology. * * * Published more than 50 academic papers and applied for 8 domestic invention patents.
Dr. Hu Xiaonian: Professor of the Institute of Basic Medicine of China Academy of Medical Sciences, Vice Chairman of Beijing Meng Jing Hi-Tech Stem Cell Technology Co., Ltd., 199 1 obtained the Doctor of Science degree from the Institute of Basic Medicine of China Academy of Medical Sciences, 1988 participated in the national "Seventh Five-Year Plan" key project and the oncogene research of esophageal cancer in NIH population in the United States; 199 1 year participated in the national natural science foundation and doctoral research on the regulation mechanism of oncogene expression; 65438-0998 participated in a number of national natural science foundation projects (virus genes, etc. ); 1995 participated in the pilot production process of recombinant human interleukin -3 in the project of China Academy of Sciences; 200 1 participated in the "973" project to study the gene therapy of human tumors.
Dr. Hu Xiaonian's main research interests are tumor gene expression regulation and human stem cell application technology. For many years, he has been engaged in the research and development of tumor etiology, tumor gene expression and regulation, tumor gene therapy, genetic engineering drugs and cell therapy technology. He has presided over the 1 national "863" project, the sub-project leader of 1 "863", participated in the1national "863" project, and participated in many research projects such as the National Natural Science Foundation. A gene therapy delivery vector specifically targeting liver cells and a suicide gene expression vector specifically targeting liver cancer cells were constructed. He presided over the research of Inner Mongolia Science and Technology Innovation Guidance Award Fund Project "Stem Cell Industrialization and Clinical Application", participated in the Inner Mongolia Science and Technology Guidance Award Fund Project "Research and Application of Human Stem Cells in the Treatment of Major Diseases", mainly engaged in the separation, purification, identification, preservation, induced differentiation and applied technology research of human stem cells, and participated in the establishment of Inner Mongolia stem cell application technology research and development platform, Inner Mongolia stem cell industrial base and clinical application technology center. He has won the third prize of National Science and Technology Progress Award 1 time and the Science and Technology Progress Award of Ministry of Health twice. He applied for and obtained 9 national invention patents and published 4 monographs.
Dr. Han Xuehai, Vice President of Meng Jing Hi-Tech Stem Cell Technology Co., Ltd., received his Ph.D. in molecular biology from Institute of Biophysics, Chinese Academy of Sciences in 1987. He has successively served as an assistant researcher at the State Key Laboratory of Sensing Technology, Institute of Electronics, Chinese Academy of Sciences (1996), an associate professor Tsinghua University (1996), an associate researcher at the Institute of Biophysics, Chinese Academy of Sciences (1999), a fixed staff and independent project leader of the State Key Laboratory of Biomacromolecules, and a distinguished researcher at the Japanese Science and Technology Department (1999). China Academy of Sciences-Royal Society Exchange Scholar (1999), invited researcher of New Jersey Medical University (UMDNJ) (2002), lecturer of University of Pittsburgh Medical College and University of Pittsburgh Medical Center (UPMC), fixed staff.
Dr. Han Xuehai has a rich multi-disciplinary background, including physics, engineering, biophysics and biochemistry, molecular biology, immunology, basic medicine and so on. Engaged in research and development of stem cell-related industries, including national key scientific and technological projects (2), major projects (2), key projects (2) and 3 projects of National Institutes of Health. 1990 won the third prize of scientific and technological progress of China Academy of Sciences, published more than 40 academic papers, and was authorized by invention patents 10.
Dr. Zhu Qing, Vice President of Meng Jing Hi-Tech Stem Cell Technology Co., Ltd., received his doctorate in medicine from the Department of Pathology and Molecular Medicine of McMaster University in 2004, won the Excellent Thesis Award from the North American Gastrointestinal Association in Orlando, Florida, USA in 2006, won the International Mucosal Immunity Conference in 2007, won the Excellent Report Award from the Center of Excellence of the National Cancer Institute and the American Federal Government Technology Transformation Award in 2008. In 2008, he attended the Targeted Immunotherapy and Vaccine Summit held in Boston, Massachusetts, USA. The combined action mechanism of Toll was discovered, which played an important guiding role in vaccine development. Accurately design the vaccination strategy of a new oral anti-HIV vaccine. Has become an important subject development direction of NIH in the United States, engaged in stem cell and immunology research. Focus on the immune system reconstruction and immune regulation mechanism of stem cells. To study the complications of stem cell therapy for diabetes; To study the mechanism of tumor biotherapy and tumor immunosuppression.
Dr. Zhu Qing's main academic achievements include tumor cellular immunity, tumor biotherapy, intestinal mucosal immunity, natural immune mechanism and vaccine strategy research. The combined mechanism of Toll discovered by him provides a brand-new theoretical basis and application basis for vaccine research and development, and the concept of remote transmembrane immune protection expounded by him is of great guiding significance for vaccine prevention and treatment of sexually transmitted diseases. Dr. Zhu is engaged in stem cell and immunology research, mainly engaged in the research and development of stem cells in immune system reconstruction and immune regulation mechanism, stem cell treatment of diabetes and its complications, large-scale preparation of stem cells and induced differentiation. Participated in and presided over the Inner Mongolia Autonomous Region Science and Technology Innovation Guidance Award Fund Project, published academic papers in important international journals such as J Clin Invest, PNAS, Immunity, J Immunol, MucosalImmunol, Molimmune, and applied for US and international patents 1 respectively.
Dr. Fan Xiaoxiang, vice president of project department of Meng Jing Hi-Tech Stem Cell Technology Co., Ltd., graduated from German university, 20 10? His main research interests are molecular biology and cell biology. During his Ph.D., he mainly engaged in the research of prosecution point activation and cell signal transduction pathway after DNA damage, the industrial transformation of scientific research projects (at the same time, he was engaged in the research of protein purification procedures conforming to GMP standards, the optimization and establishment of standard operating procedures conforming to GMP standards, etc. ). Since 2002, he has worked in the Clinical Research Center of Vakhnin University in the Netherlands and Duisburg-Essen University in Germany, mainly studying the signal transduction coupling mechanism between the repair protein and the prosecution point after controlling DNA loss, and discovering the quantitative mechanism of protein focus formation/residue and cell cycle activation after DNA damage. He has published papers in Radiation Research, Biotechnology Journal, Biotechnology Newsletter and Brewing.
Dr. Fan Xiaoxiang's specific project is "Study on the Standardization of CIK Cell Therapy Industrialization". The purpose of this project is to establish an industry standard of CIK cell therapy service that is suitable for China's national conditions, and finally provide a scientific basis for the country to formulate corresponding cell therapy service standards. Among them, "lymphocyte separation liquid with high biological safety" is applying for national patent. In view of FDA's great concern about the safety of cell therapy products and China's imperfect laws and regulations in this field, the industrialized implementation of this patent will help our government regulatory agencies to make up for the shortcomings of existing laws and regulations. He was responsible for the development of cytokine products in the First Laboratory of Beijing Institute of Biological Products, and participated in the Federal Scientific Research (BMBF) fund in the Clinical Research Center of Duisburg-Essen University, Germany. Published articles in J Gen Virol, Radiation Res and other magazines.
Dr. Li Dinggang, the chief medical officer of Beijing Meng Jing Hi-Tech Stem Cell Technology Co., Ltd. 1982 graduated from Nanjing Medical University, and then worked in the general surgery department of Beijing Friendship Hospital affiliated to Beijing Capital Medical University, engaged in the clinical, teaching and scientific research work of general surgery department. 1990- 1995 went to the tumor surgery laboratory of Johns Hopkins University School of Medicine to do postdoctoral research. Personal research results are published in international first-class medical journals such as JCI (Journal of Clinical Research), Surgery (Journal of Surgery), Shock (Shock) and Circulation (Journal of Circulation).
In 2004, Dr. Li Dinggang was transferred to Beijing Haidian Hospital to establish the first cancer gene therapy center in China, and served as the director and chief physician of the center. In April 2007, the first comprehensive treatment center of gene biotherapy and hyperthermia was established in Beijing Yanhua Hospital, and served as the director, chief medical expert and chief physician of the cancer center. In the past four years, Chief Physician Li Dinggang has treated a large number of cancer patients from all over China in Beijing Haidian Hospital and Beijing Yanhua Hospital Cancer Gene Therapy Center, and also attracted people from the United States, Canada, Mexico, Panama, Germany, Britain, Denmark, Sweden, Norway, Netherlands, Spain, Romania, Greece, Turkey, Singapore, Malaysia, India, Pakistan, Philippines, Thailand, Vietnam and Hong Kong. This great medical achievement has been widely concerned by the international oncology community and the media. Since the Italian newspaper Liberty first published the report of gene therapy center in May 2005, the medical achievements of Chief Physician Li Dinggang have been reported by more than 20 international media. For example, Businessweek, Washington post, CBS, Red Herring, German Economic Weekly, Canadian National Television -CTV, British Television 4, German Television 2, Swedish National Television and Danish National Television. Turkish national television, Korean national television and other mainstream media in the world made large-scale positive reports on Haidian Hospital and Beijing Yanhua Hospital Cancer Gene Therapy Center from different angles, which won international honor for China Hospital.
Chief physician Li Dinggang is currently a member of the International Society of Cryosurgery, a director of the China Medical Biotechnology Association, a director of the China Branch of the World Association of Pain Physicians, a member of the editorial board of the China Journal of Medical Biotechnology, a member of the Beijing Branch of the China Anti-cancer Society and a member of the General Surgery Society of the Beijing Branch of the Chinese Medical Association.